A dual-label time-resolved fluorescence immunoassay for screening of osteoporosis based on simultaneous detection of C-terminal telopeptide (β-CTX) and aminoterminal propeptide (P1NP) of type I procollagen

References

• Lash RW, Nicholson JM, Velez L, et al. Diagnosis and management of osteoporosis. Prim Care. 2009;36:181–198.
   PubMed Web of Science ®Google Scholar
• Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60:324–333.
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Wang Z. Osteoporosis knowledge of students in relevant healthcare academic programs. J Osteoporos. 2012;2012:1.
   Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359–2381.
   PubMed Web of Science ®Google Scholar
• Sankaran SK. Osteoporosis prevention and treatment. Pharmacological management and treatment implications. Drugs Aging. 1996;9:472–477.
   PubMed Web of Science ®Google Scholar
• Luo ZB, Zhang LJ, Zeng RJ, et al. Near-infrared light-excited core–core–shell UCNP@Au@CdS upconversion nanospheres for ultrasensitive photoelectrochemical enzyme immunoassay. Anal Chem. 2018;90:9568–9575.
   PubMed Web of Science ®Google Scholar
• Xu YJ, Zhang P, Wang Z, et al. Determination of the activity of telomerase in cancer cells by using BSA-protected gold nanoclusters as a fluorescent probe. Mikrochim Acta. 2018;185:198.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu XZ, Li YF, et al. A dual-label time-resolved fluorescence immunoassay (TRFIA) for screening of coronary atherosclerosis based on simultaneous detection of Lp-PLA2 and HsCRP. Immunol Lett. 2017;182:12–17.
   PubMed Web of Science ®Google Scholar
• Webber CE. Photon absorptiometry, bone densitometry and the challenge of osteoporosis. Phys Med Biol. 2006;51:R169–R185.
   PubMed Web of Science ®Google Scholar
• Cabral HW, Andolphi BF, Ferreira BV, et al. The use of biomarkers in clinical osteoporosis. Rev Assoc Med Bras (1992). 2016;62:368–376.
   PubMed Web of Science ®Google Scholar
• Hegedus D, Ferencz V, Lakatos PL, et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res. 2002;17:1961–1967.
   PubMed Web of Science ®Google Scholar
• Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the elecsys β-crosslaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem. 2001;47:1410–1414.
   PubMed Web of Science ®Google Scholar
• Fassbender WJ, Godde M, Brandenburg VM, et al. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes. Adv Med Sci (Poland). 2009;54:1–6.
   PubMed Web of Science ®Google Scholar
• Samoszuk M, Leuther M, Hoyle N. Role of serum P1NP measurement for monitoring treatment response in osteoporosis. Biomark Med. 2008;2:495–508.
   PubMed Web of Science ®Google Scholar
• Liu TC, Chen MJ, Ren ZQ, et al. Development of an improved time-resolved fluoroimmunoassay for simultaneous quantification of C-peptide and insulin in human serum. Clin Biochem. 2014;47:439–444.
   PubMed Web of Science ®Google Scholar
• Lin GF, Liu TC, Zou LP, et al. Development of a dual-label time-resolved fluoroimmunoassay for the detection of a-fetoprotein and hepatitis B virus surface antigen. Luminescence. 2013;28:401–406.
   PubMed Web of Science ®Google Scholar
• Xie M, Huang H, Hang J, et al. Evaluation of the analytical and clinical performances of time-resolved fluoroimmunoassay for detection carcinoma antigen 50. J Immunoassay Immunochem. 2015;36:265–283.
   PubMedGoogle Scholar
• Yu LS, Reed SA, Golden MH. Time-resolved fluorescence immunoassay (TRFIA) for the detection of Escherichia coli O157:H7 in apple cider. J Microbiol Methods. 2002;49:63–68.
   PubMed Web of Science ®Google Scholar
• Zhang ZW, Wang D, Li J, et al. Monoclonal antibody-europium conjugate-based lateral flow time-resolved fluoroimmunoassay for quantitative determination of T-2 toxin in cereals and feed. Anal Methods. 2015;7:2822–2829.
   Web of Science ®Google Scholar
• Costa OR, Stangé G, Verhaeghen K, et al. Development of an enhanced sensitivity bead-based immunoassay for real-time in vivo detection of pancreatic β-cell death. Endocrinology. 2015;156:4755–4760.
   PubMed Web of Science ®Google Scholar
• Srivastava M, Deal C. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med. 2002;18:529–555.
   PubMed Web of Science ®Google Scholar
• Bonnick SL, Shulman LP. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006;119:S25–S31.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Lix LM, Yogendran MS, et al. Temporal trends in obesity, osteoporosis treatment, bone mineral density, and fracture rates: a population-based historical cohort study. J Bone Miner Res. 2014;29:952–959.
   PubMed Web of Science ®Google Scholar
• Hammett-Stabler CA. The use of biochemical markers in osteoporosis. Clin Lab Med. 2004;24:175–197.
   PubMed Web of Science ®Google Scholar
• Horiguchi I, Ohtake T, Saito S. Bone biochemical markers and bone mineral density among osteoporosis patients who were seen in a pain clinic. Pain Clin. 2002;14:61–68.
   Web of Science ®Google Scholar
• Iglesias P, Arrieta F, Pinera M, et al. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol (Oxf). 2011;75:184–188.
   PubMed Web of Science ®Google Scholar
• Yeap BB, Alfonso H, Chubb SA, et al. Proportion of undercarboxylated osteocalcin and serum P1NP predict incidence of myocardial infarction in older men. J Clin Endocrinol Metab. 2015;100:3934–3942.
   PubMed Web of Science ®Google Scholar